Accelerated Pharma is a late-stage pharmaceutical company with a potential blockbuster cancer drug, Picoplatin, which is progressing towards Phase II trials. Picoplatin is a next generation platinum-based chemotherapy that may offer significant improvement over current standards of care.

Accelerated Pharma’s mission is to enhance cancer drug development by repositioning late-stage clinical projects utilizing a proprietary genomic platform that targets patients who have the greatest chances of responding to our pipeline of therapies. The company’s management has a proven track record for guiding clinical development and obtaining regulatory approval. The team has secured approval for eight different drugs with wide adoption from regulatory authorities. The company is pursuing commercial approval for Picoplatin in the US and other key markets based on safety and efficacy data demonstrated to date. Accelerated Pharma plans to finalize its choice of lead indication following anticipated FDA guidance